Market Access News | pharmaphorum

News

Servier bags FDA okay for glioma drug from $2bn Agios buy

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.

News

NICE backs osteoporosis drug, but diagnosis is an obstacle

Around 14,000 women in England may soon be able to access a new treatment for osteoporosis after NICE backed routine NHS use of Theramex's Eladynos.

News

BioMarin keeps but scales down Roctavian gene therapy ops

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the busin

News

Actinium's radioligand filing plans scuppered by FDA

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radiol

News

FDA panel backs Zevra's arimoclomol, after earlier rejection

An FDA advisory committee has recommended approval of Zevra Therapeutics' arimoclomol for the ultra-rare disorder Niemann-Pick disease, three years after the regulator rejected the drug.

News

GSK bags sought-after Jemperli okay in endometrial cancer

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions f

Servier bags FDA okay for glioma drug from $2bn Agios buy

NICE backs osteoporosis drug, but diagnosis is an obstacle

BioMarin keeps but scales down Roctavian gene therapy ops

Actinium's radioligand filing plans scuppered by FDA

FDA panel backs Zevra's arimoclomol, after earlier rejection

GSK bags sought-after Jemperli okay in endometrial cancer

Amgen's Imdelltra scores again in small cell lung cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks